Induction of beta-2-microglobulin release in vitro by chronic lymphocytic leukaemia cells: relation to total protein synthesis

被引:12
作者
Vilpo, J
Vilpo, L
Hurme, M
Vuorinen, P
机构
[1] Tampere Univ Hosp, Dept Clin Chem, Lab Mol Haematol, FIN-33521 Tampere, Finland
[2] Univ Tampere, Sch Med, FIN-33521 Tampere, Finland
[3] Tampere Univ Hosp, Dept Clin Microbiol, FIN-33521 Tampere, Finland
关键词
beta-2-microglobulin; B-lymphocytes; chronic lymphocytic leukaemia; cytokines; leukaemia; lymphocytic; human; phorbols;
D O I
10.1016/S0145-2126(99)00109-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The in vitro production of beta(2)-M by B-CLL cells from 27 patients was investigated. In all cases, low spontaneous beta(2)-M release was observed. The production of beta(2)-M was enhanced to various extents when induced with 13 different stimulants and their combinations including IL-2, TNF alpha, SAC and TPA. beta(2)-M release was 3.8-fold (range from 1.9 to 9.2-fold) in cultures stimulated with TPA (10 ng/ml), compared with the spontaneous release, and even faster if TNF alpha or IL-2 were added. A strong correlation was revealed between beta(2)-M production and the total protein synthesis of leukaemic cells when the latter was assessed using C-14-L-leucine incorporation. Hence, both beta(2)-M release and leucine incorporation are promising activation markers for CLL B-lymphocytes. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:913 / 920
页数:8
相关论文
共 23 条
[1]   SERUM LEVELS OF HELPER FACTORS (IL-1-ALPHA, IL-1-BETA AND IL-6), T-CELL PRODUCTS (SCD4 AND SCD8), SIL-2R AND BETA-2-MICROGLOBULIN IN PATIENTS WITH B-CLL AND BENIGN B-LYMPHOCYTOSIS [J].
AGUILARSANTELISES, M ;
LOFTENIUS, A ;
LJUNGH, C ;
SVENSON, SB ;
ANDERSSON, B ;
MELLSTEDT, H ;
JONDAL, M .
LEUKEMIA RESEARCH, 1992, 16 (6-7) :607-613
[2]   PROPOSALS FOR THE CLASSIFICATION OF CHRONIC (MATURE) B-LYMPHOID AND T-LYMPHOID LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
JOURNAL OF CLINICAL PATHOLOGY, 1989, 42 (06) :567-584
[3]  
BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[4]  
2-V
[5]  
DIGIOVANNI S, 1989, ACTA HAEMATOL-BASEL, V81, P181
[6]   IMMUNOLOGICAL ASPECTS OF A CASE OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER [J].
FRANCO, A ;
MUNOZ, C ;
ARANDA, I ;
CABEZAS, A ;
PERDIGUERO, M ;
PRADOS, C .
AMERICAN JOURNAL OF NEPHROLOGY, 1995, 15 (02) :137-141
[7]   Serum beta 2-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma [J].
Hallek, M ;
Wanders, L ;
Ostwald, M ;
Busch, R ;
Senekowitsch, R ;
Stern, S ;
Schick, HD ;
KuhnHallek, I ;
Emmerich, B .
LEUKEMIA & LYMPHOMA, 1996, 22 (5-6) :439-447
[8]  
Henne V, 1997, ANTICANCER RES, V17, P2915
[9]   Diminished production of interleukin-6 in chronic lymphocytic leukaemia (B-CLL) cells from patients at advanced stages of disease [J].
Hulkkonen, J ;
Vilpo, J ;
Vilpo, L ;
Hurme, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 100 (03) :478-483
[10]   GM-CSF raises serum levels of beta(2)-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia [J].
Itala, M ;
Pelliniemi, TT ;
Remes, K .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 94 (01) :129-132